drugset

drugset / Trial / NCT02988297

Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

NCT02988297 ↗

Phase 2 Withdrawn Revalesio Corporation

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).

Timeline

Start: 2026-10
Primary completion: 2028-11
Completion: 2028-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RNS60	Other / unclassified	—	Inhaled

Indications